Targets › VWF
6 programs from 6 companies in 7 trials: 3 Phase 3, 2 Phase 4, 1 Phase 1, 1 Phase 2; Hematology, Other; next expected readout Dec 2026.
Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma. (UniProt, P04275)
Open in Phaseline: the race on VWF, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University Hospital, Basel, Switzerland | Wilate 1:1 balanced mixture of von Willebrand Factor and Coagulation Factor VIII | F8, VWF | Phase 4 | Bleeding | Nov 2027 |
| Grifols Biologicals | Alphanate SD/HT Factor VIII/von Willebrand Factor (vWF) concentrate | F8, VWF | Phase 4 | Von Willebrand Disease | – |
| Takeda | Vonicog Alfa von Willebrand factor exogenous protein | VWF | Phase 3 | Von Willebrand Disease (VWD) | Nov 2027 |
| Unity Health Toronto | Wilate Von Willebrand Factor and Factor VIII concentrate | VWF, F8 | Phase 3 | Von Willebrand Diseases | Dec 2027 |
| Medical University of Vienna | BT200 Aptamer directed against the A1 domain of von Willebrand factor | VWF | Phase 2 | Von Willebrand Disease (VWD), Type 2 | – |
| University of Virginia | Von Willebrand Factor Human von Willebrand factor exogenous protein | VWF | Phase 1 | Bleeding Disorder | Dec 2026 |
Von Willebrand Disease (VWD) (2) Von Willebrand Diseases (1) Bleeding Disorder (1) Bleeding (1) Von Willebrand Disease (VWD), Type 2 (1) Von Willebrand Disease (1)
protein or peptide (3), small molecule (3)
Takeda (1) Unity Health Toronto (1) University of Virginia (1) University Hospital, Basel, Switzerland (1) Medical University of Vienna (1) Grifols Biologicals (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.